NCT06056323View on ClinicalTrials.gov

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

September 19, 2025

Study Completion Date

March 19, 2026

Conditions
Solid Tumor, Adult
Interventions
DRUG

HB0045 Drug Product

Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.

Trial Locations (3)

44718

RECRUITING

The Gabrail Pharmacology Phase 1 Research Center LLC, Canton

301402

NOT_YET_RECRUITING

UT M.D. Anderson Cancer Center, Houston

02215

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Gabrail Cancer Center Research

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY